Seed funding supports new approaches to tackling infectious diseases
Targeted funding is helping researchers at the Wesfarmers Centre of Vaccines and Infectious Diseases (WCVID), based at The Kids Research Institute Australia, test innovative infectious disease research ideas and explore their potential.

Targeted funding is helping researchers at the Wesfarmers Centre of Vaccines and Infectious Diseases (WCVID), based at The Kids Research Institute Australia, test innovative infectious disease research ideas and explore their potential. This support is driving new approaches to vaccine development, infant immunity and child-friendly treatments.
Dr Hannah Thomas, Dr Sonia McAlister and Dr Maria Emilia Dueñas were recently awarded grants valued up to $30,000 each through WCVID’s Seed Funding program to advance projects aligned with the Centre's four Flagship Programs.
These programs focus on accelerating Aboriginal health equity, safeguarding the early years through infection identification and prevention, recognising and responding to life-threatening infections, and combatting antimicrobial resistance.
Dr Hannah Thomas will use her grant to make treatment for childhood tinea easier and more acceptable for young patients.
Although oral terbinafine is an effective treatment for fungal skin infections, the adult-sized tablets often need to be cut into quarters to give children the correct dose. This exposes them to the medicine’s extremely bitter taste, making it harder for children to take and potentially affecting whether they complete treatment.
Building on earlier WCVID-funded work to develop a child-friendly, chocolate-flavoured chewable tablet, Dr Thomas will investigate how best to evaluate the new formulation in children. The project will test a less invasive blood sampling method for future studies and gather insights from children and families about their experiences and treatment priorities.
The findings will help shape a family-centred clinical study, bringing the formulation one step closer to improving treatment options for children with tinea.
Dr Sonia McAlister has been awarded funding for two separate projects exploring how maternal vaccination influences infant immunity.
Her first project will establish a new laboratory testing capability in Western Australia to measure how effectively antibodies from a baby's blood can kill whooping cough bacteria.
While vaccination during pregnancy protects newborns against whooping cough, questions remain about how maternal vaccination may influence babies' responses to their own childhood vaccines. By measuring antibody function, rather than simply antibody levels, the research will provide a clearer picture of protection and help inform future maternal vaccination strategies.
Her second project seeks to establish Australia's first pneumococcal Systems Serology capability, offering a more comprehensive way to assess infant immune responses to pneumococcal vaccination.
Current testing largely measures the concentration of one type of antibody, providing only a partial picture of immunity. By examining multiple antibody characteristics, the project aims to uncover aspects of protection that conventional testing may miss and improve understanding of how maternal vaccination influences infant immunity.
Dr Maria Emilia Dueñas will use her grant to advance the development of a potential needle-free vaccine against Group A Streptococcus (Strep A).
Strep A causes hundreds of millions of infections worldwide each year and can lead to serious complications, including acute rheumatic fever and rheumatic heart disease. Aboriginal and Torres Strait Islander children experience a disproportionately high burden of Strep A infections.
Dr Dueñas will investigate a novel vaccine approach designed to strengthen the body's natural defences in the nose and throat, where Strep A infections first take hold. The project will test whether the vaccine platform can generate antibodies capable of preventing the bacteria from attaching to cells, laying the groundwork for a potential child-friendly vaccine.
WCVID extends its gratitude to the Grant Review Panel (GRP), comprising Dr Alec Truswell, Dr Hannah Thomas, Jaimee Rich, Jacqui Hume, Dr Janessa Pickering, Dr Keerthi Anpalagan, Leila Zandi, Dr Ritika Kar Bahal, Dr Sharon Clark, Shaun Wright, Dr Tamara Veselinović and Dr Tim Pesch.
We also wish to acknowledge the valuable contributions of GRP Chair Associate Professor Kathryn Ramsey and PhD observer Sophie Hughes.
First published Thursday 19 November 2026.
View all news articles